Title:
びまん性大細胞型Ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法
Document Type and Number:
Japanese Patent JP7142612
Kind Code:
B2
Abstract:
Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
Inventors:
Matthew William Brunel Trotel
Patrick Hagner
Courtney G. Havens
Rajesh Chopra
Anita Gandhi
Anke Kripel
Maria Yingling Wang
mic blader
Susana Starlini Kout
Yang Ren
Paul Hollenbak
Kyle Macbeth
Patrick Hagner
Courtney G. Havens
Rajesh Chopra
Anita Gandhi
Anke Kripel
Maria Yingling Wang
mic blader
Susana Starlini Kout
Yang Ren
Paul Hollenbak
Kyle Macbeth
Application Number:
JP2019120643A
Publication Date:
September 27, 2022
Filing Date:
June 28, 2019
Export Citation:
Assignee:
Celgene Corporation
International Classes:
C12Q1/6886; A61K31/454; A61K31/517; A61K31/5377; A61K45/00; A61P1/16; A61P25/00; A61P35/00; A61P35/02; C12Q1/02; C12Q1/6883; G01N33/15; G01N33/50; G01N33/53
Domestic Patent References:
| JP2010504530A | ||||
| JP2014514579A |
Foreign References:
| WO2013106686A1 | ||||
| WO2012153187A2 | ||||
| US20070099209 | ||||
| WO2014004990A2 |
Attorney, Agent or Firm:
Toru Ishikawa